NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
Innovations in Haematology Cell Therapy at ASH 2025
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Strengthening EU Pharmaceutical Supply Security Through the Critical Medicine...